New York, NY – Investors who purchased securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023, and December 26, 2025, are being encouraged by the Rosen Law Firm to seek legal counsel ahead of a critical deadline. A securities class action lawsuit has been filed, and investors have until April 7, 2026, to move the Court to be appointed as lead plaintiff in the case.
The lawsuit alleges that Inovio Pharmaceuticals made false and/or misleading statements throughout the specified period, impacting investor confidence and potentially causing financial harm. This action underscores the importance of investor rights and the potential for legal recourse when companies are accused of misrepresenting key information. Understanding these rights is crucial for those who may have been affected by the alleged misstatements.
Rosen Law Firm, a global investor rights law firm, specializes in securities class actions and shareholder derivative litigation. The firm has a notable track record, including achieving what it claims was the largest ever securities class action settlement against a Chinese Company. According to the firm, it was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked among the top four firms since 2013, recovering hundreds of millions of dollars for investors. In 2019, the firm reportedly secured over $438 million for investors, and founding partner Laurence Rosen was named a “Titan of Plaintiffs’ Bar” by Law360 in 2020.
Details of the Allegations
The core of the lawsuit centers around claims that Inovio Pharmaceuticals failed to disclose critical information regarding its CELLECTRA device manufacturing and the prospects for its INO-3107 Biologics License Application (BLA). Specifically, the suit alleges that the company misrepresented the following:
- Manufacturing deficiencies related to the CELLECTRA device.
- The likelihood of submitting the INO-3107 BLA to the U.S. Food and Drug Administration (FDA) by the second half of 2024.
- Insufficient data to support the INO-3107 BLA’s eligibility for accelerated approval or priority review by the FDA.
- An overstatement of the overall regulatory and commercial potential of INO-3107.
These alleged misrepresentations, the lawsuit claims, led to materially false and misleading statements that ultimately harmed investors when the true details came to light. The potential damages suffered by investors are a key focus of the class action.
What Investors Need to Grasp
If you purchased Inovio Pharmaceuticals (NASDAQ: INO) securities during the “Class Period” – between October 10, 2023, and December 26, 2025 – you may be entitled to compensation without incurring out-of-pocket fees or costs through a contingency fee arrangement. To participate in the Inovio class action, investors can submit information through the Rosen Law Firm’s website: https://rosenlegal.com/submit-form/?case_id=52847. Alternatively, they can contact Phillip Kim, Esq., toll-free at 866-767-3653 or via email at [email protected].
It’s important to note that a class has not yet been certified. So that investors are not currently represented by counsel unless they retain their own. Investors have the right to select their own legal representation or remain an absent class member. Serving as lead plaintiff does not guarantee a share in any potential recovery, but it does allow for a more active role in directing the litigation.
Rosen Law Firm emphasizes the importance of selecting experienced counsel with a proven track record in securities class actions. The firm cautions investors to be wary of firms that may lack the necessary expertise or resources, acting instead as intermediaries.
Investors can follow Rosen Law Firm for updates on LinkedIn, Twitter, and Facebook.
Disclaimer: This information is for informational purposes only and does not constitute legal advice. Investors should consult with a qualified legal professional for advice tailored to their specific circumstances.
The April 7, 2026, deadline is fast approaching, and investors considering legal action are encouraged to act promptly to protect their rights. The outcome of this case will be closely watched by investors and industry observers alike, as it could set precedents for future securities litigation.
Please share this information with anyone who may be affected and join the conversation in the comments below.
